Alpha-synucleinopathy affects around 15 million people worldwide and expected to double in next 20 years. There is an unmet medical need for the accurate detection and treatment of alpha-synucleinopathy. We aim to enable early detection and personalized medicine for alpha-synucleinopathy with novel small molecule-based PET imaging biomarker that bind to alpha-synuclein with high sensitivity and specificity. Our unique selling points include precision, digital readout, and noninvasiveness. We will 1) help Pharma and Biotechs to bring alpha-synucleinopathy disease-modifying drugs to market as efficacy biomarker; 2) enable early detection of alpha-synucleinopathy in patients and 3) serve as companion diagnostics for personalized medicine in alpha-synucleinopathy patients receiving treatments.